Evolus (EOLS) Competitors

Evolus (NASDAQ:EOLS) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability.

Does the media prefer EOLS or IMVT?

In the previous week, Immunovant had 2 more articles in the media than Evolus. MarketBeat recorded 14 mentions for Immunovant and 12 mentions for Evolus. Immunovant's average media sentiment score of 0.39 beat Evolus' score of 0.25 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evolus	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunovant	3 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is EOLS or IMVT more profitable?

Immunovant has a net margin of 0.00% compared to Evolus' net margin of -22.33%. Immunovant's return on equity of -77.94% beat Evolus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolus	-22.33%	-847.60%	-22.15%
Immunovant	N/A	-77.94%	-69.82%

Which has better earnings & valuation, EOLS or IMVT?

Evolus has higher revenue and earnings than Immunovant. Evolus is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$266.27M	2.91	-$61.69M	-$0.81	-15.06
Immunovant	N/A	N/A	-$259.34M	-$2.62	-7.09

Does the MarketBeat Community favor EOLS or IMVT?

Evolus received 227 more outperform votes than Immunovant when rated by MarketBeat users. However, 78.11% of users gave Immunovant an outperform vote while only 72.97% of users gave Evolus an outperform vote.

Company	Underperform	Outperform
Evolus	Outperform Votes 359 72.97%	Underperform Votes 133 27.03%
Immunovant	Outperform Votes 132 78.11%	Underperform Votes 37 21.89%

Do analysts rate EOLS or IMVT?

Evolus currently has a consensus target price of $24.67, indicating a potential upside of 102.25%. Immunovant has a consensus target price of $41.00, indicating a potential upside of 120.58%. Given Immunovant's higher probable upside, analysts clearly believe Immunovant is more favorable than Evolus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Immunovant	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.00

Which has more risk and volatility, EOLS or IMVT?

Evolus has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.

Do institutionals and insiders believe in EOLS or IMVT?

90.7% of Evolus shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 6.1% of Evolus shares are owned by company insiders. Comparatively, 5.9% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Immunovant beats Evolus on 9 of the 17 factors compared between the two stocks.